Trials / Unknown
UnknownNCT00794859
Sorafenib in Previously Treated Malignant Mesothelioma
Trial of Sorafenib in Malignant Mesothelioma Previously Treated With Platinum-based Chemotherapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- King's College London · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The principal objective of the study is to investigate the effect of sorafenib on progression free survival (time until the cancer begins to grow again,) in patients with malignant mesothelioma who have had prior treatment with chemotherapy. Effectiveness of the drug will also be explored with PET scans before and during treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib | 400mg twice daily |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2009-12-01
- First posted
- 2008-11-20
- Last updated
- 2009-08-04
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00794859. Inclusion in this directory is not an endorsement.